Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation

Brain Research

Volumn 968, Issue 1, 2003, Pages 102-113

  Shin, Yangmee ^a   White, Beatrix H ^a   Uh, Misook ^a   Sidhu, Anita ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

4 Hydroxynonenal; Multiple system atrophy; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

2 NONENAL; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 HYDROXYNONENAL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; ALDEHYDE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 5 RECEPTOR; FORSKOLIN; PYROPHOSPHORIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN MEMBRANE; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; ENZYME INHIBITION; LIPID PEROXIDATION; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM;

EID: 0037418629     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)04279-8     Document Type: Article

References (65)

1. Adams J.D., Odunze I.N. Oxygen free radicals and Parkinson's disease. Free Radic. Biol. Med. 10:1991;161-169.
2. Beal M.F., Ferrante R.J., Browne S.E., Matthews R.T., Kowall N.W., Brown R.H. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 42:1997;644-654.
3. Benedetti A., Casini A.F., Ferrali M. Red cell lysis coupled to the peroxidation of liver microsomal lipids. Compartmentalization of the hemolytic system. Res. Commun. Chem. Pathol. Pharmacol. 17:1997;519-528.
4. Benzi G., Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol. Aging. 16:1995;661-674.
5. Blanc E.M., Keller J.N., Fernandez S., Mattson M.P. 4-Hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. Glia. 22:1998;149-160.
6. Blanc E.M., Kelly J.F., Mark R.J., Waeg G., Mattson M.P. 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G alpha(q/11). J. Neurochem. 69:1997;570-580.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. Brambilla G., Sciaba L., Faggin P., Maura A., Marinari U.M., Ferro M., Esterbauer H. Cytotoxicity, DNA fragmentation and sister-chromatid exchange in Chinese hamster ovary cells exposed to the lipid peroxidation product 4-hydroxynonenal and homologous aldehydes. Mutat. Res. 171:1986;169-176.
9. Butterfield D.A. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem. Res. Toxicol. 10:1997;495-506.
10. Chan P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21:2001;2-14.
11. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann. N Y Acad. Sci. 899:2000;112-120.
12. Curzio M., Esterbauer H., Di Mauro C., Cecchini G., Dianzani M.U. Chemotactic activity of the lipid peroxidation product 4-hydroxynonenal and homologous hydroxyalkenals. Biol. Chem. Hoppe Seyler. 367:1986;321-329.
13. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F. ells, Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9:1994;92-97.
14. Ekinci F.J., Malik K.U., Shea T.B. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. J. Biol. Chem. 274:1999;30322-30327.
15. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11:1991;81-128.
16. Fleuranceau-Morel P., Barrier L., Fauconneau B., Piriou A., Huguet F. Origin of 4-hydroxynonenal incubation-induced inhibition of dopamine transporter and Na+/K+ adenosine triphosphate in rat striatal synaptosomes. Neurosci. Lett. 277:1999;91-94.
17. Gingrich J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16:1993;299-321.
18. Hall E.D. Inhibition of lipid peroxidation in central nervous system trauma and ischemia. J. Neurol. Sci. 134:(Suppl.):1995;S79-S83.
19. 3H]dopamine: impact of ascorbic acid and glutathione. J. Neurochem. 63:1994;1126-1132.
20. Junn E., Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320:2002;146-150.
21. Jurgens G., Lang J., Esterbauer H. Modification of human low-density lipoprotein by the lipid peroxidation product 4-hydroxynonenal. Biochim. Biophys. Acta. 875:1986;103-114.
22. Kalra J., Rajput A.H., Mantha S.V., Chaudhary A.K., Prasad K. Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Mol. Cell. Biochem. 112:1992;181-186.
23. Keller J.N., Mark R.J., Bruce A.J., Blanc E.M., Rothstein J.D., Uchida K., Waeg G., Mattson M.P. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience. 80:1997;685-696.
24. Keller J.N., Pang Z., Geddes J.W., Begley J.G., Germeyer A., Waeg G., Mattson M.P. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 69:1997;273-284.
25. 1 rat somatomammotrophic cells. J. Neurochem. 64:1995;2118-2124.
26. 125I-SCH 23982 binding but increases the affinity of dopamine for D1 dopamine receptors. J. Neurochem. 63:1994;2093-2098.
27. Le W., Rowe D., Xie W., Ortiz I., He Y., Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21:2001;8447-8455.
28. Lovell M.A., Ehmann W.D., Mattson M.P., Markesbery W.R. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging. 18:1997;457-461.
29. Mark R.J., Lovell M.A., Markesbery W.R., Uchida K., Mattson M. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68:1997;255-264.
30. Mark R.J., Pang Z., Geddes J.W., Uchida K., Mattson M.P. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17:1997;1046-1054.
31. Marx J.L. Oxygen free radicals linked to many diseases. Science. 235:1987;529-531.
32. Mattson M.P., Tomaselli K., Rydel R E. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 621:1993;35-49.
33. McCall M.R., Tang J.Y., Bielicki J.K., Forte T.M. Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler. Thromb. Vasc. Biol. 15:1995;1599-1606.
34. Miranda S., Opazo C., Larrondo L.F., Munoz F.J., Ruiz F., Leighton F., Inestrosa N.C. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog. Neurobiol. 62:2000;633-648.
35. Munson P., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 60:1980;220-239.
36. Natarajan V., Scribner W.M., Taher M.M. 4-Hydroxynonenal, a metabolite of lipid peroxidation, activates phospholipase D in vascular endothelial cells. Free Radic. Biol. Med. 15:1993;365-375.
37. O'Dowd B.F. Structures of dopamine receptors. J. Neurochem. 60:1993;804-816.
38. Offen D., Hochman A., Gorodin S., Ziv I., Shirvan A., Barzila A., Melamed E. Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. Adv. Neurol. 80:1999;265-269.
39. Parola M., Bellomo G., Robino G., Barrera G., Dianzani M.U. 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antiox. Redox Signal. 1:1999;255-284.
40. Rabinovic A.D., Lewis D.A., Hastings T.G. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience. 101:2000;67-76.
41. Rossi M.A., Di Mauro C., Dianzani M.U. Experimental studies on the mechanism of phospholipase C activation by the lipid peroxidation products 4-hydroxynonenal and 2-nonenal. Int. J. Tissue React. 23:2001;45-50.
42. Rossi M.A., Di Mauro C., Esterbauer H., Fidale F., Dianzani M.U. Activation of phosphoinositide-specific phospholipase C of rat neutrophils by the chemotactic aldehydes 4-hydroxy-2,3-trans-nonenal and 4-hydroxy-2,3-trans-octenal. Cell Biochem. Funct. 12:1994;275-280.
43. Ruef J., Rao G.N., Li F., Bode C., Patterson C., Bhatnagar A., Runge M.S. Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal. Circulation. 97:1998;1071-1078.
44. Sayre L.M Zelasko D.A., Harris P.L., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68:1997;2092-2097.
45. Sela S., Sidhu A. Sulfhydryl groups of renal D1A dopamine receptors: differential sensitivity of receptors to N-ethylmaleimide in normotensive and hypertensive rats. J. Hypertens. 14:1996;615-622.
46. Selley M.L. (E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. 25:1998;169-174.
47. Sidhu A., Kassis S., Kebabian J., Fishman P.H. Sulfhydryl group(s) in the ligand binding site of the D-1 dopamine receptor: specific protection by agonist and antagonist. Biochemistry. 25:1986;6695-6701.
48. Sidhu A., Kebabian J.W. An iodinated ligand identifying the D-1 dopamine receptor. Eur. J. Pharmacol. 113:1985;437-440.
49. Sidhu A., Kimura K., Vachvanichsanong P. Induction of G protein-independent agonist high-affinity binding sites of D-1 dopamine receptors by beta-mercaptoethanol. Biochemistry. 33:1994;11246-11253.
50. Siems W.G., Hapner S.J., van Kuijk F.J. 4-Hydroxynonenal inhibits Na (+)-K(+)-ATPase. Free Radic. Biol. Med. 20:1996;215-223.
51. Spencer J.P., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71:1998;2112-2122.
52. 2-resistant cell lines. Do aldehydic by-products of lipid peroxidation contribute to oxidative stress? Biochem. J. 267:1990;453-459.
53. Spitz D.R., Sullivan R.R., Roberts R.J. Glutathione dependent metabolism and detoxification of 4-hydroxy-2-nonenal. Free Radic. Biol. Med. 11:1991;415-423.
54. Sunahara R.K., Guan H.-C., O'Dowd B.F., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H., Niznik H.B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature (London). 350:1991;614-619.
55. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P. Jr., Davis R.E., Parker W.D. Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40:1996;663-671.
56. Toyokuni K., Uchida K., Okamoto K., Hattori-Nakakuri Y., Hiai H., Stadtman E.R. Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc. Natl. Acad. Sci. U.S.A. 91:1994;2116-2120.
57. Uchida K., Kanematsu M., Morimitsu Y., Osawa T., Noguchi N., Niki E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J. Biol. Chem. 273:1998;16058-16066.
58. Uchida K., Shiraishi M., Naito Y., Torii Y., Nakamura Y., Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. 4-hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J. Biol. Chem. 274:1999;2234-2242.
59. Uchida K., Stadtman E.R. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4544-4548.
60. Uchida K., Stadtman E.R. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J. Biol. Chem. 268:1993;6388-6393.
61. Uchida K., Toyokuni S., Nishikawa K., Kawakishi S., Oda H., Hiai H., Stadtman E.R. Michael addition-type 4-hydroxy-2-nonenal adducts in modified low-density lipoproteins: markers for atherosclerosis. Biochemistry. 33:1994;12487-12494.
62. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130:2000;184-208.
63. White B.H., Sidhu A. Increased oxidative stress in renal proximal tubules of the spontaneously hypertensive rat: a mechanism for defective dopamine D1A receptor/G-protein coupling. J. Neurochem. 64:1998;2118-2124.
64. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2696-2701.
65. Zhang Y., Dawson V. L, Dawson T.M. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 7:2000;240-250.